Mirtazapine
Brand: Remeron (US/EU) / Mirtaz (IN) / Remer (BD)
Antidepressant
NaSSA (Noradrenergic and specific serotonergic antidepressant)
Pharmacokinetics
| Half-life | 30 hours |
| Tmax | 2 h |
| Bioavailability | 50 % (approx) |
| Protein Binding | 85 % |
| Volume of Distribution | 4 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Sedation strongest at low dose (paradoxical); less sexual dysfunction compared to SSRIs. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Weight gain, increased appetite, sedation, dry mouth
Contraindications:
Concurrent MAOI use
Precautions:
Caution in obesity; sedation may impair driving; lower sexual side effect burden than SSRIs.